1. Pirnay JP, Verbeken G, Ceyssens PJ, Huys I, De Vos D, Ameloot C, Fauconnier A. 2018.
    The magistral phage
    Viruses, 10(2), 64.
  2. Rohde C, Resch G, Pirnay JP, Blasdel BG, Debarbieux L, Gelman D, Górski A, Hazan R, Huys I, Kakabadze E, Łobocka M.
    Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains.
    Viruses, 10(4), 178.
  3. Pirnay JP, Merabishvili M, Van Raemdonck H, De Vos D, Verbeken G. 2018.
    Bacteriophage Production in Compliance with Regulatory Requirements.
    In Bacteriophage Therapy (pp. 233-252). Humana Press, New York, NY.
  4. Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, Weitz JS, Debarbieux L.
    Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen.
    Cell host & microbe, 22(1), 38-47.
  5. Debarbieux L, Pirnay JP, Verbeken G, De Vos D, Merabishvili M, Huys I, Patey O, Schoonjans D, Vaneechoutte M, Zizi M, Rohde C. 2016.
    A bacteriophage journey at the European Medicines Agency
    FEMS microbiology letters, 363(2).
  6. Sarkera SA, Sultanaa S, Reuteler G, Moinec D, Descombes P, Charton F, Bourdin G, McCallin S, Ngom-Bru C, Neville T, Akter M, Huq S, Qadri D, Talukdar K, Kassam M, Delley M, Loiseau C, Deng Y, El Aidy S, Berger B, Brüssow H. 2016.
    Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh
    EBioMedicine 4: 124–137.
  7. Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, Corte-Real S, Debarbieux L, Dublanchet A, De Vos D, Gabard J, Garcia M, Goderdzishvili M, Górski A, Hardcastle J, Huys I, Kutter E, Lavigne R, Merabishvili M, Olchawa E, Parikka KJ, Patey O, Pouilot F, Resch G, Rohde C, Scheres J, Skurnik M, Vaneechoutte M, Van Parys L, Verbeken G, Zizi M, Van den Eede G. 2015.
    Quality and safety requirements for sustainable phage therapy products.
    Pharm Res 32(7):2173-9.
  8. Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S, Zizi M, Pirnay JP. 2014.
    Experimental phage therapy of burn wound infection: difficult first steps.
    Int J Burns Trauma. 26;4(2):66-73. 
  9. Verbeken G1, Pirnay JP, Lavigne R, Jennes S, De Vos D, Casteels M, Huys I. 2014.
    Call for a dedicated European legal framework for bacteriophage therapy.
    Arch Immunol Ther Exp (Warsz). 62(2):117-29.
  10. Rose T, Verbeken G, De Vos D, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S, Zizi M, Pirnay J. 2014
    Experimental phage therapy of burn wound infection: difficult first steps 
    Int J Burn Trauma 4(2): 66-73.
  11. Chan BK, Abedon ST, Loc-Carrillo C. 2013.
    Phage cocktails and the future of phage therapy
    Future Med 8(6): 769-783
  12. Abedon ST, Kuhl SJ, Blasdel BG, Kutter E. 2011.
    Phage treatment of human infections
    Bacteriophage 1(2): 66–85.
  13. Wright A, Hawkins CH, Anggård EE, Harper DR. 2009. 
    A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
    Clin Otolaryngol 34: 349-357.
  14. Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M, Pirnay J-P. 2007. 
    The European regulatory conundrum of phage therapy.
    Future Microbiol 2: 485-491.
  15. Merabishvili M, Pirnay J-P, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M. 2009. 
    Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.
    PloS One 2009;4: e4944.
  16. Górski A, Kniotek M, Perkowska-Ptasi?ska A, Mróz A, Przerwa A, Gorczyca W, Dabrowska K, Weber-Dabrowska B, Nowaczyk M. 2006. 
    Bacteriophages and transplantation tolerance.
    Transplant Proc 38: 331-333.
  17. Weber-Dabrowska B, Mulczyk M, Gorski A. 2000. 
    Bacteriophage therapy of bacterial infections: an update of our institute’s experience.
    Arch Immunol Therap Experiment 48: 547-551.
  18. Hughes KA, Sutherland IW, Jones MV. 1998. 
    Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase.
    Microbiol 144: 3039-3047.
  19. d’Hérelle F. 1925. 
    Essai de traitement de la peste bubonique par le bactériophage.
    La Presse Med 33: 1393-1394.


  1. Chanishvili N, Sharp R. 2009. Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi, Georgia.  
    A literature review of the practical application of Bacteriophage Research.